Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): A multicenter stepped-wedge cluster randomized controlled trial by Mackay, T.M. (Tara M.) et al.
STUDY PROTOCOL Open Access
Impact of nationwide enhanced
implementation of best practices in
pancreatic cancer care (PACAP-1): a
multicenter stepped-wedge cluster
randomized controlled trial
T. M. Mackay1 , F. J. Smits2, A. E. J. Latenstein1, A. Bogte3, B. A. Bonsing4, H. Bos5, K. Bosscha6, L. A. A. Brosens7,8,
L. Hol9, O. R. C. Busch1, G. J. Creemers10, W. L. Curvers11, M. den Dulk12, S. van Dieren1, L. M. J. W. van Driel13,
S. Festen14, E. J. M. van Geenen15, L. G. van der Geest16, D. J. A. de Groot17, J. W. B. de Groot18, N. Haj Mohammad19,
B. C. M. Haberkorn20, J. T. Haver21, E. van der Harst22, G. J. M. Hemmink23, I. H. de Hingh24, C. Hoge25, M. Y. V. Homs26,
N. C. van Huijgevoort27, M. A. J. M. Jacobs28, E. D. Kerver29, M. S. L. Liem30, M. Los19, H. Lubbinge31, S. A. C. Luelmo32,
V. E. de Meijer33, L. Mekenkamp34, I. Q. Molenaar35, M. G. H. van Oijen36, G. A. Patijn37, R. Quispel38, L. B. van Rijssen1,
T. E. H. Römkens39, H. C. van Santvoort35, J. M. J. Schreinemakers40, H. Schut41, T. Seerden42, M. W. J. Stommel43,
A. J. ten Tije44, N. G. Venneman45, R. C. Verdonk3, J. Verheij46, F. G. I. van Vilsteren47, J. de Vos-Geelen48, A. Vulink49,
C. Wientjes50, F. Wit51, F. J. Wessels52, B. Zonderhuis53, C. H. van Werkhoven54, J. E. van Hooft27†, C. H. J. van Eijck55†,
J. W. Wilmink36†, H. W. M. van Laarhoven36†, M. G. Besselink1*† and for the Dutch Pancreatic Cancer Group
Abstract
Background: Pancreatic cancer has a very poor prognosis. Best practices for the use of chemotherapy, enzyme
replacement therapy, and biliary drainage have been identified but their implementation in daily clinical practice is
often suboptimal. We hypothesized that a nationwide program to enhance implementation of these best practices
in pancreatic cancer care would improve survival and quality of life.
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Methods/design: PACAP-1 is a nationwide multicenter stepped-wedge cluster randomized controlled superiority trial. In
a per-center stepwise and randomized manner, best practices in pancreatic cancer care regarding the use of (neo)adjuvant
and palliative chemotherapy, pancreatic enzyme replacement therapy, and metal biliary stents are implemented in all 17
Dutch pancreatic centers and their regional referral networks during a 6-week initiation period. Per pancreatic center, one
multidisciplinary team functions as reference for the other centers in the network. Key best practices were identified from
the literature, 3 years of data from existing nationwide registries within the Dutch Pancreatic Cancer Project (PACAP), and
national expert meetings. The best practices follow the Dutch guideline on pancreatic cancer and the current state of the
literature, and can be executed within daily clinical practice. The implementation process includes monitoring, return visits,
and provider feedback in combination with education and reminders. Patient outcomes and compliance are monitored
within the PACAP registries. Primary outcome is 1-year overall survival (for all disease stages). Secondary outcomes include
quality of life, 3- and 5-year overall survival, and guideline compliance. An improvement of 10% in 1-year overall survival is
considered clinically relevant. A 25-month study duration was chosen, which provides 80% statistical power for a mortality
reduction of 10.0% in the 17 pancreatic cancer centers, with a required sample size of 2142 patients, corresponding to a
6.6% mortality reduction and 4769 patients nationwide.
Discussion: The PACAP-1 trial is designed to evaluate whether a nationwide program for enhanced implementation of
best practices in pancreatic cancer care can improve 1-year overall survival and quality of life.
Trial registration: ClinicalTrials.gov, NCT03513705. Trial opened for accrual on 22th May 2018.
Keywords: Pancreatic cancer, Survival, Quality of life, Stepped-wedge cluster randomized controlled trial, Implementation,
Best practices, Chemotherapy, Biliary drainage, Pancreatic enzyme replacement therapy, Registry
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Background {a}
It is estimated that pancreatic cancer will be the second
most common cause of cancer-related mortality by 2030 in
Europe [1]. Without treatment, the median survival is only 3
to 6 months. Some 15–20% of patients with pancreatic
cancer are amenable to surgical resection combined with
adjuvant chemotherapy [2]. However, even after resection,
the median overall survival is only 11–25 months [1, 3]. In
patients in whom it is possible to perform a microscopic rad-
ical resection median survival increases to 3 to 4 years [3–5].
The Dutch Pancreatic Cancer Project
The Dutch Pancreatic Cancer Project (PACAP) aims to
improve outcomes of patients in all stages of pancreatic
cancer. PACAP was launched in 2013 as an initiative of
the national multidisciplinary Dutch Pancreatic Cancer
Group (DPCG, www.dpcg.nl) [6]. In a period of 6 years,
PACAP aimed primarily to improve outcome and quality
of life for pancreatic cancer patients in the Netherlands.
This is achieved through one of the largest nationwide
collaborative outcomes registration and biobanking
projects on pancreatic cancer in the world, which provides
unique opportunities for improving care for these patients
and developing new diagnostic and treatment strategies.
From the start, PACAP included several registries,
including the Dutch Pancreatic Cancer Audit (DPCA), the
Netherlands Cancer Registry (NCR), the Dutch Pancreas
Biobank (PancreasParel), patient-reported outcome mea-
sures (PROMs), and an online expert panel [7–9]. Details
on PACAP registries are listed in Appendix 1.
The PACAP-1 trial {6b} {15}
In 2014, 78% of 2393 patients diagnosed with pancreatic
cancer in the Netherlands died within 1 year (www.
cijfersoverkanker.nl). These numbers illustrate the severity
of this disease and the need for improvement of treatment
and clinical outcomes. From the literature and the first 3
years of PACAP, fairly straightforward points of
improvement in care and guideline compliance for patients
with pancreatic cancer in the Netherlands were identified.
Systematic reviews of guideline dissemination and
implementation strategies showed that compliance by
health-care workers, specifically medical doctors, is poor
[10, 11]. A recent study demonstrated that compliance with
the 2012 Dutch pancreatic cancer guideline was low (Fig. 1)
[12]. In addition, regional differences in (type of) treatment
and clinical outcomes have been identified. For example, the
use of adjuvant chemotherapy after pancreatoduodenectomy
for pancreatic cancer per DPCG center varied between 26
and 74% in 1195 Dutch patients (2008–2013) [13]. Signifi-
cant differences were also present in the type of palliative
chemotherapy given to 345 patients with metastatic disease
(Fig. 2). Patients with metastatic disease who were treated in
high-volume chemotherapy or surgical centers had better
survival compared to lower volume centers [14]. While ad-
ministration of palliative systemic chemotherapy doubled in
the elderly in the Netherlands between 2005 and 2013 (13%
vs. 30%), it was still relatively low compared with
population-based studies from other western countries [15].
The PACAP-1 trial aims to enhance the implementa-
tion of key best practices in the 17 Dutch pancreatic
centers with their associated regional networks, using a
nationwide stepped-wedge cluster randomized con-
trolled trial (RCT). PACAP-1 is unique in that it involves
all relevant medical specialties and all Dutch hospitals
treating patients with pancreatic cancer. PACAP-1 will
use the registries already included in PACAP to audit
current practice and improve adherence to best practices
and synoptic reporting in the Netherlands for pancreatic
cancer patients, including the Dutch evidence-based
guideline on pancreatic cancer [16]. Most importantly,
with the PACAP infrastructure, the levels of implemen-
tation and compliance and the effect on patient out-
comes can be assessed. We hypothesize that survival and
quality of life will improve for pancreatic cancer patients
in the Netherlands by a program to enhance implemen-
tation of best practices.
Methods/design
Study setting {9}
The PACAP-1 trial will implement best practices in and
collect data from all hospitals (e.g., academic, top-clinical,
general) in the Netherlands. A list of the DPCG centers
where pancreatic surgery is performed can be found at
www.dpcg.nl.
Primary aim {7}
The primary aim of PACAP-1 is to evaluate whether a na-
tionwide program for enhanced implementation of best
practices can improve 1-year overall survival by 10% in all
pancreatic cancer patients in the Netherlands. Ten per-
cent was considered to be clinically relevant.
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Secondary aims {7}
Secondary aims are to evaluate whether enhanced
implementation of key best practices can improve quality of
life (main secondary objective) and clinical outcomes (3- and
5-year overall survival and treatment complications). An-
other aim is to improve the use of nationwide standardized
“best practice” reports by radiologists, surgeons, pathologists,
medical oncologists, and gastroenterologists. Hereby, we aim
to optimize data registry with key parameter and synoptic
reporting that will lead to efficient and high-quality data col-
lection. Finally, we aim to improve participation in DPCG
RCTs, especially those which aim to improve survival and/or
quality of life.
PACAP-1 trial design {8} {13}
The PACAP-1 trial is a nationwide stepped-wedge cluster
RCT which aims for enhanced implementation of best prac-
tices in all 17 DPCG pancreatic cancer centers and their
Fig. 1 Guideline compliance among 2564 patients treated for pancreatic or periampullary cancer in the Netherlands in 2010 and 2012. MDT multidisciplinary
team. Adjuvant chemotherapy, percentage of patients receiving adjuvant chemotherapy after tumor resection for pancreatic carcinoma. Discussed in MDT
meeting, percentage of patients discussed within a MDT meeting. Waiting time, percentage of patients who started curative treatment within three weeks of
final MDT meeting. * Not available for 2010
Fig. 2 Type of palliative chemotherapy given to 345 patients with metastasized pancreatic cancer in 2015 in the Netherlands in pancreatic and non-
pancreatic centers (NCR data). CAPOX capecitabine and oxaliplatin, 5FU 5-fluorouracil, FOLFIRINOX folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin
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respective referral networks. Per pancreatic center and net-
work, one regional pancreatic cancer team serves as refer-
ence for the other centers in the network. The pancreatic
cancer team included at least a medical oncologist, a gastro-
enterologist, and a surgeon, regularly together with a special-
ized nurse. This trial was designed in adherence to the
CONSORT statement for cluster randomized trials [17] and
extension for stepped-wedge trials [18], and SPIRIT guide-
lines for clinical trials [19]. For an overview of PACAP-1, see
the SPIRIT figure (Fig. 3) and the SPIRIT checklist (Supple-
mentary materials).
A schematic overview of the stepped-wedge trial design
is provided in Fig. 4. In a step-wise manner, each cluster
will cross-over from control (current practice) to interven-
tion (best practice) phase. Each cluster contains one
DPCG center and its referral region (Fig. 5), and therefore
the number of sequences is equal to the number of par-
ticipating centers. At the start of the study all clusters will
be in the control phase. After 25months, all 17 clusters
will have crossed over to the intervention phase.
The duration of the trial is determined by the required
sample size. Details of the sample size calculation are
described in the “Sample size calculation” section. The order
in which the clusters will cross-over is randomized [20, 21].
To achieve effective implementation of PACAP-1 best
practices, a structured 6-week wash-in phase was designed
(Appendix 2). Also, in this timeframe the study team will
discuss with the local pancreatic cancer team how to imple-
ment best practices efficiently. It is important to avoid con-
tamination of best practice for clusters still in the control
phase. Therefore, details on PACAP-1 best practices will not
be shared with local clinicians before the transfer to the
intervention phase. In the analysis of PACAP-1, every clus-
ter is their own control because of the cluster RCT design.
Study population {10} {15}
All patients with pancreatic cancer in the Netherlands.
Patient inclusion criteria {10}
Patients with pathologically or clinically diagnosed
pancreatic ductal adenocarcinoma, all ages and all stages.
Patient exclusion criteria {10}
None.
Center inclusion criteria {10}
All 17 centers of the DPCG with their respective referral
network. Each DPCG center performs at least 20
pancreatoduodenectomies (PDs) annually. Each center
already has a coordinating role for pancreatic cancer for
its regional network (Fig. 5). It is expected that the
enhanced implementation of best practices will have an
Fig. 3 Schedule of enrolment, interventions, and assessments of PACAP-1 according to SPIRIT guidelines
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impact in the entire local network. A survey was
conducted among DPCG centers to identify peripheral
centers that mainly refer to their DPCG center. Outcomes
of this survey were checked with NCR data and
discrepancies only occurred for two centers. With these
centers and the particular DPCG centers, it was discussed
in what region the center would fit best.
Center exclusion criteria {10}
There are no specific center exclusion criteria.
Study endpoints {12}
Primary endpoint
The primary endpoint is 1-year overall survival.
Secondary endpoints
Secondary study endpoints are divided into intervention (e.g.,
quality of life, 3- and 5- year survival, and treatment
complications such as chemotherapy toxicity), process
measure (e.g., proportion of post-pancreatectomy patients re-
ceiving adjuvant chemotherapy, and proportion of patients re-
quiring biliary drainage receiving a metal stent), registry (e.g.,
proportion of patients registered for PROMs or in DPCA,
and proportion of patients where the CT scan checklist was
used), and other outcomes (e.g., proportion of patients in-
cluded in other DPCG prospective trials). See Supplementary
materials for a detailed list of the secondary endpoints.
Sample size calculation {14}
PACAP-1 is a superiority trial with 1-year overall sur-
vival as primary endpoint, which will be extracted from
NCR survival data. The sample size calculation was
based on the data from Table 1.
The required sample size was calculated using the
formula for stepped-wedge designs [22]. Sample sizes were
calculated for different effect sizes, different intra-cluster co-
efficients, for 80% or 90% power, and for the DPCG centers
and for all of the Netherlands separately, using a cluster
autocorrelation (CAC) of 1 [23] and a two-sided alpha of
Fig. 5 Schematic representation of 17 Dutch Pancreatic Cancer
Group centers (large dots) and their respective referral networks and
centers (smaller dots) per color. Note that referral centers may refer
patients to more than one pancreatic center and therefore this
figure is only for illustration
Fig. 4 Schematic representation of PACAP-1 stepped-wedge cluster randomized controlled trial. DPCG Dutch Pancreatic Cancer Group
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0.05 (Table 2). Subsequently, it was reverse calculated which
effect sizes could be determined with 80% and 90% power
given a fixed study duration (hence a fixed sample size) of
25months for the different other assumptions (Table 2). For
logistical reasons inherent to successful implementation of
different (discipline transcending) interventions, a shorter
study duration was not considered.
An improvement of 10% in 1-year overall survival for all
patients with pancreatic cancer in the Netherlands is consid-
ered clinically relevant, and could be established following
the PACAP-1 interventions. A 25-month study duration
was chosen, which provides 80% statistical power for an ab-
solute mortality reduction of 10.0% and 90% power for a re-
duction of 11.5% in the 17 pancreatic cancer centers, with a
required sample size of 2142 patients. For all of the
Netherlands, assuming the intracluster correlation coeffi-
cient (ICC) will be higher, the corresponding sample size
provides 80% power for an absolute mortality reduction of
6.6% and 90% power for a reduction of 7.6% (Table 2).
Intervention phase: PACAP-1 best practices {11a}
To determine key best practices, points of improvement for
three key medical specialties (medical oncology,
gastroenterology, and surgery) were identified from literature
and the first 3 years of PACAP (July 2014–July 2017). These
are divided into intervention and registry categories (Fig. 6).
Best-practice treatments aim to improve survival, clinical
outcomes, and quality of life. Best-practice registrations aim
to optimize data registry with key parameter and synoptic
reporting that will lead to efficient and high-quality data col-
lection. PACAP-1 interventions are listed in Appendix 3 in
Table 3 per medical specialism. An overview of PACAP pro-
jects is presented in Appendix 1. Background and details per
best practice are found in the Supplementary materials.
Best practice treatments
All treatments follow the current the Dutch guideline on
pancreatic cancer [16] and the literature.
Treatment-1: Optimal patient information and use of
(neoadjuvant, adjuvant, and palliative) chemotherapy.
Treatment-2: Pancreatic enzyme replacement therapy
(PERT) and referral to dietician in case of exocrine
pancreatic insufficiency (EPI).
Treatment-3: Metal stents for biliary drainage.
Best practice registration
Registration-1: Use of checklist for radiology reports of
pancreatic cancer.
Registration-2: Use of standardized table with intra-
operative events in operation report and complications
of surgical treatment in discharge letters.
Registration-3: Use of nationwide standard for synoptic
reporting of pancreatic cancer pathology from PALGA,
the nationwide network and registry of histo- and
cytopathology of the Netherlands.
Registration-4: Report of World Health Organization
(WHO) performance status.
Additional best practices
Other-1: Inclusion of pancreatic cancer patients in
PACAP PROMs registry.
Other-2: Participation in PancreasParel biobank.
Other-3: Pathologic confirmation in patients with
(suspected) metastatic and locally advanced pancreatic
cancer (LAPC).
Other-4: Participation in DPCG RCTs.
Table 2 Power for effect size given fixed sample size
Population N p0 p1 RD ICC Power Interpretation
25-month study duration (including 5.8-week wash-in period)
DPCG 2142 0.65 0.550 − 0.100 0.0184 0.8 80% power for
true reduction
of 10.0%
DPCG 2142 0.65 0.535 − 0.115 0.0184 0.9 90% power for
true reduction
of 11.5%
All NL 4769 0.78 0.714 − 0.066 0.0368 0.8 80% power for
true reduction
of 6.6%
All NL 4769 0.78 0.704 − 0.076 0.0368 0.9 90% power for
true reduction
of 7.6%
All NL 4769 0.78 0.722 − 0.058 0.0092 0.8 80% power for
true reduction
of 5.8%
All NL 4769 0.78 0.712 − 0.068 0.0092 0.9 90% power for
true reduction
of 6.8%
N sample size, p0 current 1-year mortality, p1 expected 1-year mortality,
RD risk difference, ICC intra-cluster correlation coefficient, CAC cluster
autocorrelation, DPCG Dutch Pancreatic Cancer Group, NL the Netherlands
Table 1 Unpublished data from the Netherlands Cancer
Registry of new patients diagnosed with pancreatic cancer in
the year 2014
New patients diagnosed in DPCG centers 1075
One-year mortality rate in DPCG centers 702/1075
65%
New patients in the Netherlands 2393
One-year mortality rate in the Netherlands 1855/2393
78%
Intra-cluster coefficient (95% CI) between DPCG
centers for one-year mortality
Approach A1: 0.0185
(0.0132–0.0575)
Approach B2: 0.0183
(0.0131–0.0560)
1 Method A from the AOD library in R uses generalized linear mixed model
2 Method B from the AOD library in R uses generalized linear mixed model
with Monte Carlo simulations
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Control phase: current practices
Current practice will be left to the discretion of the
healthcare providers in the control phase. Centers will
not learn the details of the best practices until the 6-
week wash-in period of their region.
National expert meeting
In preparation of the PACAP-1 trial, a national expert meet-
ing was organized for one oncologist and/or one surgeon
per DPCG center to improve support and buy-in, and to
optimize the design of the trial including the three interven-
tion best practices (i.e., 1) optimizing chemotherapy, 2) EPI
treatment, and 3) biliary drainage with metal stents). To
minimize contamination in the study we chose to invite only
one specialist per center. Oncologists and surgeons working
in 11 DPCG centers and a representative of the Netherlands
Comprehensive Cancer Organization (IKNL) were present.
Specialists from the other six DPCG centers were informed
on discussed topics by email and agreed. Specific details on
best practices were not shared, but extensive background
and logistic information was provided, and an elaborate dis-
cussion on what best practices should entail was conducted.
Ultimately, consensus was reached on the trial design and
crucial parts of the three intervention best practices were
identified. The shared opinion of the experts was that
PACAP-1 should aim for the following points:
1. Optimization of patient information and use of
chemotherapy
a. 70% of patients with a resected tumor should
receive adjuvant chemotherapy
b. 60% of patients with LAPC should receive
chemotherapy
c. 40% of patients with metastasized disease should
receive palliative chemotherapy
d. All pancreatic cancer patients should be discussed
in a DPCG or regional multidisciplinary team
(MDT), with the exception of a small predefined
subgroup (i.e., metastasized patients with WHO
performance status III–IV)
2. Optimization of PERT and referral to dietician
3. Optimization of use of metal stents for biliary drainage
Randomization, blinding, and treatment allocation {16a}
{16b} {16c} {17}
The same randomization order is used as in the PORSCH
trial (NCT03400280), a stepped-wedge cluster RCT on the
standard of care for postoperative complications after pan-
creatic surgery, and the PACAP-1 trial, which runs near
simultaneously in all DPCG centers in the Netherlands.
The reason to use the same randomization order was to
obtain an equally long period of optimized standard of care
for postoperative complications after pancreatic surgery
before switching to the PACAP-1 intervention phase,
resulting in homogenous treatment impact throughout
centers. Randomization of the 17 pancreatic centers was
performed using R statistics software. Stratification was
used for center volume of pancreatic resections a year (>
45 vs. ≤ 45). The median value of 45 was based on data
from the DPCA 2014–2015). The randomization sequence
was unknown to all participating centers and clinicians. Be-
cause of the design of PACAP-1, it is not feasible to blind
healthcare providers to the best practice treatments and
registrations. All PACAP-1 research data are obtained from
existing encoded PACAP registries (NCR, DPCA, and
PROMs), warranting (pseudo-)anonymization of patients.
Study procedures {11c}
No specific study procedures are used and no concomitant
care and interventions are prohibited during the trial. All best
Fig. 6 Schematic representation of PACAP-1 best practices. PERT pancreatic enzyme replacement therapy, EPI exocrine pancreatic insufficiency,
POC postoperative conclusion, PALGA nationwide network and registry of histo- and cytopathology of the Netherlands, WHO World Health
Organization performance status
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practices are part of current clinical care. PACAP-1 aims to
assess the impact of enhanced implementation of current best
practices. Therefore, the aim is to improve standard of care
compliance by informing, stimulating, and reminding local
clinicians per cluster to follow best practice interventions out-
lined by PACAP-1. Best practice procedures, identified from
literature and PACAP, include all interventions documented
in the “Intervention phase: best practices” section and Appen-
dix 3 in Table 3. Treatment as usual according to best prac-
tice will continue after the study finishes.
Withdrawal centers {11b}
Because of the stepped-wedge cluster RCT design of
PACAP-1, it is important that all randomized DPCG centers
complete the trial, so an unequal distribution of patients be-
tween current and best practice arms is prevented. However,
if a center drops out of the study the randomization order
will be maintained. Patients treated in a center that dropped
out during this trial will still be accounted for in the final
analysis, according to intention-to-treat analysis. If a center
stops performing pancreatic surgery, the study will proceed
with this center and its referral network.
Replacement centers after withdrawal
All 17 DPCG centers participate in PACAP-1 and there-
fore hospitals cannot and will not be replaced after
withdrawal.
Study duration
Planning of the PACAP-1 trial started in PACAP year three
(November 2016) and the actual accrual of patients started
in May 2018 after obtaining local approval in all participating
centers. The implementation phase of the trial will run for
25months, and the expected implementation end date is July
2020. Follow-up for the primary endpoint will last up until
July 2021 and for secondary endpoints up until July 2025.
Statistical analyses {20a} {20b} {20c}
Outcomes of all patients with pancreatic cancer in the
Netherlands will be evaluated before and after the wash-in
period (i.e., current practice vs. best practice). Patients will
be assigned to current or best practice based on the date
of first treatment related to pancreatic cancer (i.e., biliary
stent placement, chemotherapy, or primary resection). In
case of no treatment or best-supportive care, date of diag-
nosis will determine assignment to current or best prac-
tice. Follow-up time is based on date of diagnosis for all
patients. For patients diagnosed in a non-DPCG center,
the assignment to current or best practice will depend on
the affiliated DPCG center, which will be determined be-
fore the start of the study. Primary analysis will be per-
formed with an intention-to-treat analysis according to
the randomization order and cross-over dates. If imple-
mentation is not performed as scheduled, secondary
analysis will be performed according to a per protocol
analysis. In the primary analysis, we will use the intention-
to-treat principle and patients will be assigned control or
intervention according to what was applicable at the time
they received their first cancer treatment (i.e., biliary
drainage, chemotherapy, or resection). In a secondary per
protocol analysis, patients that started in the control
period but received part of their cancer treatment during
the intervention period will be assigned to the intervention
group (e.g., patients who underwent resection in the
current practice phase, yet started adjuvant chemotherapy
in the best practice phase). Patients diagnosed during the
wash-in period will be described but will be excluded from
the primary analysis, yet will be included in a secondary
analysis. The primary comparison between current and
best practice will be performed for patients from all hospi-
tals in the Netherlands. Effect estimates with 95% confi-
dence intervals (CI) will be reported. All p values will be
based on a two-sided test. P values of less than 0.05 will
be considered statistically significant.
Handling of missing data {20c}
Missing data on baseline characteristics will be imputed
by multiple imputation techniques. Outcome data will not
be imputed and patients who are lost to follow-up within
1 year will be censored at the date of loss to follow-up.
Complete and multiple imputed data analysis will be per-
formed to check for inconsistencies.
Baseline characteristics
Descriptive statistics will be used for analysis and
reporting of baseline characteristics. Chi-square or Fisher’s
exact test will be used to compare categorical variables be-
tween patients in current practice and those in best prac-
tice. Parametric continuous variables will be reported as
mean with standard deviation (SD) and will be compared
using the Student’s t-test. Non-parametric continuous var-
iables will be reported as median with interquartile range
(IQR) and will be compared using the Mann–Whitney U
test.
Primary outcome {20a}
One-year overall survival will be analyzed with mixed-
effects Cox proportional hazards regression models
using a random intercept for hospital and a random
slope on intervention effect for hospital. The analysis
will be adjusted for (calendar) time and for the following
baseline characteristics: age at diagnosis and tumor stage
at diagnosis using the Union for International Cancer
Control (UICC) tumor/node/metastasis (TNM) eighth
edition (2018) classification and staging system for pan-
creatic cancer.
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Secondary outcomes {20a}
Quality of life will be analyzed using mixed-effects linear
regression models, with a random effect per DPCG center.
Primary analysis will be performed with area under the
curve (AUC) at baseline and follow-up at 3, 6, 9, and 12
months or until death or dropout. Exploratory analysis
will be performed with AUC for time points until 3- and
5-year follow-up or until death or dropout, delta analysis,
quality adjusted life years (QALY), and for one time point.
Adjustment for random and fixed effects will be per-
formed similarly to the primary analysis. Model assump-
tions will be checked and, if violated, appropriate
measures will be taken to derive unbiased standard errors.
Three- and five-year overall survival will be analyzed
similarly to the primary endpoint with mixed-effects
Cox proportional hazards regression models.
Complication rates will be determined using competing
events analysis for time to first complication, corrected for
the competing event death. Analyses will be performed for
any of all complications and for each type of complication
separately. Both cause-specific hazard ratios (reflecting the
effect per day alive) and sub-distribution hazard ratios
(reflecting the overall effect) will be determined.
Other secondary outcomes will be descriptive in nature,
e.g., the proportion of patients in the intervention vs. the
control arm using PERT or receiving metal stents.
Subgroup and sensitivity analyses {20b}
Subgroup analyses will be performed for three patient
subgroups (i.e., patients with resectable, locally advanced,
and metastatic pancreatic cancer), two hospital volumes
(> 40 vs. ≤ 40 PDs per year [3]) and trial participation in
prospective DPCG trials (e.g., PREOPANC-2).
Also, subgroup analysis will be performed for
outcomes in pancreatic centers versus referring
centers. Patients are allocated to the center in which
the primary treatment (e.g., pancreatectomy or first
line chemotherapy) has been given.
Sensitivity analyses will be performed for the periods
before and after publication of the updated national
guideline on pancreatic cancer and European Society of
Gastrointestinal Endoscopy guideline on stenting.
Interim analysis {21b}
No interim analysis will be performed for study outcomes.
A study progression analysis will be performed to assess
the number of inclusions at the time point when 50% of
inclusions are expected. In the case that < 47.5% of
inclusions are acquired at that time point, the length of
the steps as described in the “Study design” section will be
increased for the remaining time of PACAP-1. As a result,
sample size will be reached and statistical power will be
maintained. Furthermore, if necessary, when PORSCH in-
creases the length of the steps, PACAP-1 will do so too, to
maintain a minimum time difference of 5 months between
wash-in phases of both studies in the same cluster.
Safety reporting {22}
PACAP-1 does not introduce new or experimental
interventions. Therefore, this trial is not expected to
introduce any additional safety or health risk for patients
compared to regular care and hence no specific safety
reporting is performed. There is no anticipated harm
and compensation for trial participation.
Handling and storage of data and documents {18a} {18b}
{19} {27} {21b}
Data will be collected through DPCA, NCR, and PROMs.
Nationwide DPCA registration, containing mostly surgical
data, is completed by local clinicians through an online
survey supported by Medical Research Data Management
(MRDM). MRDM secures privacy and safe data
management and complies with the requirements of
information safety with NEN 7510:2011 and ISO 27001:2013
certifications. An opt-out procedure is in place by which pa-
tients can refuse the use of their data. Coded DPCA data are
securely sent to the PACAP project leader every 3 months.
MRDM is the only one with access to the coding key.
NCR data, containing mostly survival, oncological,
chemo-, and/or radiotherapy information, are collected
from local medical records by trained IKNL registration
employees. An opt-out procedure is in place by which pa-
tients can refuse the use of their data. Coded NCR data will
be obtained from IKNL by the PACAP-1 research team on
request. NCR is the only one with access to the coding key.
PROM questionnaires are completed by patients either on
paper or online with the first quality of life evaluation at
baseline before index treatment. After that, questionnaires
will be sent out every 3 months in the first year, every 6
months in the second year, and every 12months for
subsequent years. After collection of paper questionnaires at
the AMC, storage and digitization happen at Profiles
(subdivision of IKNL focusing on quality of life; https://
www.profilesregistry.nl/). Online completed questionnaires
are primarily collected at Profiles. Patients sign an informed
consent form for participation. The informed consents are
available from the corresponding author on request. Coded
data will be obtained from Profiles by the PACAP-1 re-
search team at request. Profiles and the PACAP-
coordinating investigators are the only ones with access to
the coding key.
Composition of the data monitoring committee and its
role and reporting structure {21a}
Because PACAP-1 does not introduce new or experimen-
tal interventions and implements best practices from
current literature and guidelines on a health care worker
level, no data monitoring committee was needed.
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Public disclosure and publication policy {31c} {23} {25}
Final manuscript and co-authorship {31a}
PACAP-1 was registered at ClinicalTrials.gov
(NCT03513705). The results of PACAP-1 will be submit-
ted to a peer-reviewed journal regardless of study out-
come. Co-authorship will be based on the international
ICMJE guidelines. Beside the key authors (coordinating
investigators as first authors and principal investigators as
senior authors), each participating DPCG center will be
offered three authorships. Each center will determine who
these authors are, but it is advised to include a surgeon,
medical oncologist, and gastroenterologist. Additional in-
volved researchers per center can be listed as collaborator.
Publications and other studies performed during the trial {5d} {25}
Best practices are based on the current standard of care
and literature and identified improvement points from the
first years of PACAP. Publications on treatment of
pancreatic cancer during the PACAP-1-trial will be
reviewed by the PACAP-1 research team. All “practice
changing” evidence publications that conflict with the pro-
posed best practices of this trial will be reviewed by the
DPCG stakeholders. The DPCG stakeholders and
PACAP-1 research team will decide together whether best
practices should be adjusted based on the new evidence.
It is expected that several external factors will contribute
to the outcomes of PACAP-1. Firstly, the updated Dutch
national guideline on diagnosis and treatment of pancreatic
cancer and an updated European Society of Gastrointes-
tinal Endoscopy guideline on biliary stenting are expected
during our study period. Secondly, national DPCG studies
will be developed and executed. For example, the
PREOPANC-2 trial on outcomes of neoadjuvant FOLFIRI-
NOX chemotherapy vs. neoadjuvant chemoradiotherapy in
patients with resectable and borderline resectable pancre-
atic cancer has already started including patients. This
could influence outcomes of PACAP-1 and will be taken
into account in the statistical analyses if possible.
Discussion
PACAP-1 is a nationwide multicenter randomized
controlled stepped-wedge superiority trial with the aim to
improve overall survival and quality of life of patients at all
stages of pancreatic adenocarcinoma in the Netherlands by
enhanced implementation of best-practices.
Rationale for stepped-wedge cluster randomized design
A structured audit combined with provider feedback,
education, outreach visits, and reminders has been
shown to be the most effective implementation strategy
for change in patients’ care [24]. RCTs are considered
the most robust research design for establishing a causal
relationship. However, educational interventions at the
level of the physician preclude the use of individual
randomization due to contamination of the control
group. Therefore, a variant of this research method is
increasingly used: the stepped-wedge cluster RCT [25].
Data collection in such large multicenter (stepped-
wedge) RCTs is, however, often challenging. Therefore,
collection through multicenter registries such as PACAP
has recently gained interest from researchers as it is a
practical way to improve feasibility and at the same time
reduce costs for large multicenter RCTs [26].
In a systematic review evaluating 25 studies, it was found
that the stepped-wedge cluster RCT design has mainly
been applied in evaluating interventions in routine practice
[25]. Individual randomization was mostly not deemed
possible for the risk of contamination of the control group.
Also, using “classic” parallel-group design was not desirable
because the PACAP-1 trial aims to implement already pre-
viously identified and universally acknowledged “best prac-
tices” in the entire population. In a stepped-wedge cluster
RCT, clusters (e.g., centers) are randomly allocated a time
when they start with the intervention. The order in which
the clusters start the intervention is based on a
randomization process, thus effectively resulting in a staged
implementation in all clusters participating in the trial.
This design is especially useful where phased implementa-
tion is preferable (e.g., because simultaneous implementa-
tion in more clusters is not possible due to logistic
reasons), and implementation in all clusters is essential,
such as with enhanced implementation of best practices.
Additionally, this design makes differentiation from time
effects possible, and after calculating the statistical effi-
ciency for PACAP-1, the power achieved with a stepped-
wedge cluster RCT was considerably larger than that of a
parallel cluster randomized trial.
Challenges
In the design of the trial, we faced several challenges.
First, to avoid contamination in the design of this
stepped-wedge trial, only a select group of DPCG ex-
perts from every specialty was involved. Although an im-
portant aspect of this trial is nationwide support and
buy-in, it was actually not desirable to involve a large
group of clinicians throughout the country before the
actual wash-in phase of their particular center and net-
work. A downside of this could be that there is less in-
volvement and awareness of the trial.
Second, the Netherlands was divided into 17 regions
according to the 17 DPCG centers with their respective
referral networks. The referral centers usually have one
main DPCG center they refer to; however, there might be
some cross-over between regions due to geographical rea-
sons, wishes of patients, or other reasons. This will lead to
some unavoidable contamination of the trial information.
Third, with the aim to improve survival and quality of
life, implementation of a package of best practices, based
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on nationwide PACAP data, seemed the best strategy. This
will, however, make it difficult to determine the
effectiveness of each intervention separately. In addition,
we advise to include patients in ongoing DPCG trials (e.g.,
PREOPANC-2) with the similar aim of survival improve-
ment, while the individual trials advise to actively partici-
pate in PACAP-1 best practices if already implemented. A
measured effect of increased survival may therefore be
partly due to the PACAP-1 enhanced implementation and
partly due to the different individual trials. PREOPANC-2
is an individually randomized trial and will therefore not
suffer from imbalances in patient management due to the
PACAP-1 trial. However, if over time the proportion of pa-
tients enrolled in PREOPANC-2 changes, this might con-
found the prognosis of patients in the PACAP-1 trial. To
account for this, a sensitivity analysis will be performed,
but separate effects can never be measured in detail.
Fourth, every step in this trial, including the wash-in
period, accounts for 6 weeks. Therefore, a delay between
date of diagnosis or date of resection, and date of com-
mencement of chemotherapy of longer than 6 weeks will
lead to an attenuated measurement of the implementation
effect. For example, patients who undergo resection a week
before the wash-in phase and adjuvant chemotherapy is
started 8 weeks after surgery are included in the current-
practice group according to intention to treat, yet are
treated as the best-practice group. In the Netherlands, me-
dian time to adjuvant chemotherapy is 6 to 7 weeks [13],
yet due to logistical reasons it was not feasible to prolong
steps. To assess the impact of a certain delay, intention to
treat as well as per protocol analyses will be performed.
Fifth, the PACAP-1 trial was designed parallel to the
PORSCH trial, both concurrent nationwide stepped-wedge
trials. PACAP-1 used the identical randomization order as
in the PORSCH trial. We considered performing an inde-
pendent randomization for PACAP-1. However, that
would very likely have resulted in unacceptable outcomes:
i) possibly both trials would have to implement the same
DPCG center simultaneously which is too much informa-
tion at once and clinicians may lose their trial dedication;
ii) multiple combinations of the implementation order per
DPCG center would be developed (e.g., first PACAP-1 and
second PORSCH or vice versa, or PACAP-1 and PORSCH
at the same time), causing bias in trial results, and iii) it ig-
nores the fact that the PORSCH algorithm (or something
similar) will probably be the standard of care for postoper-
ative complication management in the Netherlands. There-
fore, we believe that PACAP-1 best practices should ideally
be implemented in regions that are already in the best
practice phase of the PORSCH trial. The possibility to
delay the onset of PACAP-1 was deemed unacceptable for
a guideline implementation program.
Sixth, during the trial there will be updates of two
guidelines in care of pancreatic cancer (i.e., the national
guideline on pancreatic cancer diagnostics and treatment
and the international ESGE guideline on biliary drainage).
This led to more awareness of pancreatic cancer care in
current practice and best practice phase centers. As best
practice centers are already more attentive, probably the
effect of this indirect contamination is larger in current
practice centers and may therefore eliminate part of the
implementation effect. Sensitivity analyses before and after
the publication of both updated guidelines will be
performed, but due to attention to these processes over a
longer time period, it will be difficult to account for this
effect accurately.
Seventh, due to ongoing centralization, centers may
stop performing pancreatic surgery. Such centers will,
however, remain as oncological centers for patients with
non-resectable pancreatic cancer. In such a scenario, the
randomization order will not be changed as only 20% of
patients undergo a resection and this is according to the
intention-to-treat principle.
Eighth, current practice may change during any trial that
runs for a longer period of time. In PACAP-1, for example,
the advice on adjuvant strategy in the national guideline
could change during the trial to modified FOLFIRINOX
based on the recent trial by Conroy et al [27]. As modified
FOLFIRINOX has been shown to improve survival com-
pared to older chemotherapy regimens, however, this
change will likely only positively influence survival in our
cohort and therefore may result in biased outcomes.
Implications and future aims
PACAP-1 is expected to increase awareness and knowledge
on best practices and pancreatic cancer care overall, from
university pancreatic centers to smaller non-pancreatic cen-
ters. This may lead to enhanced implementation of both
PACAP-1 best practices and other regional aspects that
came to light due to this trial (e.g., the necessity of establish-
ing a regional pancreatic MDT meeting). For this study, a
pancreatic cancer team was identified in every region which
could lead to improved multidisciplinary communication
throughout and between the different networks. This study
also identified dieticians in each network. A next step in
implementing best practices could be education of all (para-
)medical caregivers (e.g., general practitioners, physiotherap-
ist, home care, etc.) to improve awareness and knowledge
on pancreatic cancer care.
Trial status
PACAP-1 was registered with ClinicalTrials.gov on May
1st, 2018 with the identifier NCT03513705. The actual
study and recruitment start date was May 22nd, 2018.
The estimated recruitment completion date is July 9th,
2020. To date, 13/17 regional networks have undergone
the implementation phase and the trial is on schedule.
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Appendix 1
Overview of PACAP projects
The Dutch Pancreatic Cancer Audit (DPCA)—A clinical
audit focusing on surgical patients in all 17 pancreatic
cancer centers in the Netherlands. Clinical variables
(more than 100 per patient) of all pancreatic resections
performed in one of the 17 pancreatic centers in the
Netherlands are prospectively registered in the DPCA.
In 2014–2015 > 1600 and in 2016 almost 1000
pancreatic resections were registered nationwide. Cross-
checks have demonstrated > 90% and > 99% case ascer-
tainment and > 99% and > 99% data accuracy after 1 year
and in registry year 2016, respectively.
The Netherlands Cancer Registry (NCR) hosted by the
Netherlands Comprehensive Cancer Organization (IKNL)—
A national registry from 1989 onward focusing on all Dutch
patients with cancer in which they are registered from
diagnosis until death. Including pancreatic cancer in all
Dutch hospitals (DPCG and referring centers), detailed
clinical data of patients receiving chemotherapy, radiotherapy,
or no treatment are obtained by trained IKNL registration
employees in every Dutch hospital.
The Dutch Pancreas Biobank (PancreasParel)—
PancreasParel obtains blood and tissue samples from all
patients with pancreatic and periampullary cancers. The
biobank is part of the Parelsnoer Institute (www.
parelsnoer.org). Preoperative blood samples, perioperative
tissue samples (tumor tissue and normal tissue), and
postoperative blood samples are collected. Since its official
launch in February 2015, over 488 patients have been
included. Currently, 13 centers participate in the biobank,
including four academic centers and one teaching
hospital. IRB approval has been obtained in six more
centers and logistic facilities are currently being
established in these hospitals. For PACAP-1, no additional
biological specimens will be collected.
Patient Reported Outcome Measures (PROMs)—PROMs
are prospectively registered for all patients with pancreatic
and periampullary cancer starting in the winter of 2015.
After 7 months, seven academic and 11 peripheral centers in
the Netherlands had joined this initiative. Within 18months,
517 patients were included and 308 patients returned quality
of life questionnaires (i.e., response rate 60%).
An online expert panel—Online expert panel meant to
provide advice on resectability of pancreatic cancer. The
PACAP expert panel received 180 patients from nine
centers, referred between April 2015 and July 2017. Sub-
analysis of the first 79 referrals identified locally advanced
pancreatic cancer (LAPC) in 100% of cases and in 51%
(40/79) of patients there was an additional treatment or a
change in the planned treatment strategy. Of these pa-
tients, a resection with curative intention was performed
in eight patients (10%) and 28 patients (35%) were in-
cluded in a clinical trial, investigating local ablative
therapies. In all cases the expert panel advice was provided
within 1 week.
Appendix 2
Methods of implementation of PACAP-1 best practices
To achieve effective implementation of PACAP-1 best
practices, a structured wash-in phase is designed:
1. At the start of the wash-in phase, a regional “kick-off”
evening is organized by the PACAP-1 research team
at the DPCG center with presentations on details of
the interventions and logistics of PACAP-1. All in-
volved physicians and nurses from the DPCG-center
and peripheral hospitals in that region are invited.
2. At this evening, the regional pancreatic cancer team
is introduced as a central group to implement the
best practices, PACAP-1 interventions, and logistics
in that region.
3. Also, all PACAP-1 support materials will be made
available. They include the detailed protocol, the
PACAP-1 smartphone application, decision support
tools, pocketsize PACAP-1 overview, and access to
protected parts of www.pacap.nl.
4. In the first and second weeks of the wash-in phase,
introductory presentations will be given to each
medical specialty. The PACAP-1 research team will
also participate in a local MDT meeting in which
pancreatic cancer patients are discussed.
5. In weeks 3–6 of the wash-in phase, the PACAP-1
research team will discuss the progress of the im-
plementation with the regional pancreatic cancer
team and involved clinicians and nurses from per-
ipheral hospitals. With this approach, identified
points of improvement in the implementation strat-
egy will be adjusted if necessary.
Once a DPCG center and that region is in the best
practice phase, reminder visits will be scheduled and
reminder emails will be sent:
1. A 2-monthly update will be sent via email to the in-
volved clinicians and nurses with a graph that shows
the “scores” for compliance with PACAP-1. Other
DPCG-centers will be anonymized in the graph.
2. Four to six months after the wash-in phase, a re-
minder visit will be scheduled with presentations on
the progress of PACAP-1. This provides local clini-
cians and nurses the opportunity to ask questions.
3. If necessary, more update and reminder visits will
be scheduled.
Throughout PACAP-1, the regional pancreatic cancer
teams or the PACAP-1 research team will be available
for questions from anyone involved in this study.
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Appendix 3
.Table 3 List of PACAP-1 interventions per medical specialty
Medical oncology
Intervention Definition Outcome Measurement
1 Standard information and decision
support tool
Use of standard information and decision support tool for all pancreatic
cancer patient subgroups (e.g., via https://bit.do/beslisboom)
Survival NCR
2 Discussion on chemotherapy (resectable
patients)
Percentage of resectable pancreatic cancer patients with whom
Chemotherapy options are discussed in DPCG center
Survival
Quality of life
NCR
PROMs
DPCA
3 Diagnostics LAPC patient established in
DPCG center
Percentage of LAPC patients in the diagnostic phase that are discussed
in DPCG MDT meeting
Survival
Quality of life
NCR
PROMs
DPCA
4 Post-induction chemotherapy discussion
of LAPC patient in DPCG center
Percentage of LAPC patients treated with chemotherapy that are
discussed in DPCG MDT meeting after 2 months of therapy
Survival
Quality of life
NCR
PROMs
DPCA
5 PERT Percentage of patients with EPI who receive PERT Survival
Quality of life
NCR
PROMs
6 Key parameter WHO performance status
reporting
Percentage of patients with a (suspected) pancreatic malignancy, in
whom the WHO performance status is reported at first presentation.
– NCR
DPCA
7 Pre-treatment pathology confirmation Percentage of patients with (suspected) locally advanced and metastatic
pancreatic cancer, with histological or cytological proof of pancreatic
adenocarcinoma
– NCR
8 PROMs Percentage of patients with a (suspected) pancreatic malignancy who
are registered for the PACAP PROMs
– PROMs
9 Biobanking Percentage of patients receiving pancreatic resection for suspected
malignancy who are registered for the PancreasParel
– PancreasParel
Surgery
Intervention Definition Outcome Measurement
1 Medical oncology referral Percentage of patients with pancreatic cancer referred to medical
oncologist for consultation on adjuvant chemotherapy
Survival
Quality of life
NCR
PROMs
2 PERT Percentage of patients with EPI who receive PERT Survival
Quality of life
NCR
PROMs
3 Synoptic discharge letter Percentage of patients receiving pancreatic resection for a (suspected)
malignancy in whom the synoptic complication table is used in the
discharge letter
– DPCA
4 Synoptic POC Percentage of patients undergoing pancreatic resection in whom the
synoptic POC is used in the operation report
– DPCA
5 PROMs Percentage of patients receiving pancreatic resection for (suspected)
malignancy who are registered for the PACAP PROMs
– PROMs
6 Biobanking Percentage of patients receiving pancreatic resection for (suspected)
malignancy who are registered for the PancreasParel
– PancreasParel
7 Standardized complication management Standardized approach to early detection and treatment of pancreatic
fistula (PORSCH trial)
Postoperative
complications
DPCA
PROMs
PORSCH
Gastroenterology
Intervention Intervention Outcome Measurement
1 Metal stent Percentage of patients with a (suspected) pancreatic malignancy
requiring biliary drainage receiving a metal (rather than a plastic) stent
Complications NCR
DPCA
2 PERT Percentage of patients with EPI who receive PERT Survival
Quality of life
NCR
PROMs
3 Pre-treatment pathology confirmation Percentage of patients with (suspected) locally advanced and metastatic
pancreatic cancer with histological or cytological proof of pancreatic
adenocarcinoma
– NCR
Pathology
Intervention Definition Outcome Measurement
1 Synoptic reporting Percentage of patients receiving pancreatic resection for a suspected Number of R1 DPCA
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